Compare Stocks: APTO, BCLI, LSTA, and AEON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.24 -5.5%	$0.35	$0.18 ▼ $1.45	$12.01M	0.65	1.05 million shs	758,607 shs
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
BCLI Brainstorm Cell Therapeutics	$1.05 -1.9%	$1.02	$0.46 ▼ $1.69	$11.95M	0.28	20,995 shs	7,211 shs
LSTA Lisata Therapeutics	$1.65 +0.6%	$2.06	$0.99 ▼ $5.07	$14.78M	0.94	521,946 shs	32,392 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-5.46%	-23.36%	-16.97%	-66.63%	-70.27%
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
BCLI Brainstorm Cell Therapeutics	-1.87%	-6.53%	+35.33%	+40.26%	+36.36%
LSTA Lisata Therapeutics	+0.61%	-2.37%	+47.32%	-50.75%	-28.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.24 -5.5%	$0.35	$0.18 ▼ $1.45	$12.01M	0.65	1.05 million shs	758,607 shs
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
BCLI Brainstorm Cell Therapeutics	$1.05 -1.9%	$1.02	$0.46 ▼ $1.69	$11.95M	0.28	20,995 shs	7,211 shs
LSTA Lisata Therapeutics	$1.65 +0.6%	$2.06	$0.99 ▼ $5.07	$14.78M	0.94	521,946 shs	32,392 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-5.46%	-23.36%	-16.97%	-66.63%	-70.27%
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
BCLI Brainstorm Cell Therapeutics	-1.87%	-6.53%	+35.33%	+40.26%	+36.36%
LSTA Lisata Therapeutics	+0.61%	-2.37%	+47.32%	-50.75%	-28.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	2.75	Moderate Buy	$1.10	356.81% Upside
APTO Aptose Biosciences	0.00	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	0.00	N/A	N/A	N/A
LSTA Lisata Therapeutics	1.67	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest APTO, BCLI, LSTA, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	AEON AEON Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00 ➝ $1.20
8/13/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	AEON AEON Biopharma	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1.00
7/17/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
LSTA Lisata Therapeutics	$170K	87.45	N/A	N/A	$0.89 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$4.42	1.34	N/A	N/A	N/A	N/A	-994.63%	11/13/2026 (Estimated)
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$1.65	N/A	N/A	N/A	N/A	N/A	-519.50%	11/16/2026 (Estimated)
LSTA Lisata Therapeutics	-$16.59M	-$1.64	N/A	N/A	N/A	N/A	-116.08%	-90.55%	11/5/2026 (Estimated)

Latest APTO, BCLI, LSTA, and AEON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	BCLI Brainstorm Cell Therapeutics	-$0.29	-$0.35	-$0.06	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
APTO Aptose Biosciences	N/A	1.05	1.05
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
LSTA Lisata Therapeutics	N/A	3.69	3.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
APTO Aptose Biosciences	26.62%
BCLI Brainstorm Cell Therapeutics	14.33%
LSTA Lisata Therapeutics	8.94%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	9.40%
APTO Aptose Biosciences	1.33%
BCLI Brainstorm Cell Therapeutics	11.15%
LSTA Lisata Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	49.88 million	74.37 million	Not Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
BCLI Brainstorm Cell Therapeutics	40	11.38 million	8.74 million	Optionable
LSTA Lisata Therapeutics	30	9.01 million	8.15 million	Not Optionable

APTO, BCLI, LSTA, and AEON Headlines

Recent News About These Companies

Lisata Therapeutics moves forward with legal action following Kuva merger termination

August 4, 2026 | proactiveinvestors.com

Lisata Therapeutics moves forward with legal action following Kuva merger termination

August 4, 2026 | proactiveinvestors.com

Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash

August 4, 2026 | quiverquant.comQ

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

August 4, 2026 | globenewswire.com

Lisata Therapeutics stock falls after hours: Here's why

July 23, 2026 | msn.com

Lisata Therapeutics Extends Merger Timeline with Kuva Labs

July 17, 2026 | tipranks.com

Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing

June 26, 2026 | globenewswire.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

June 15, 2026 | newsfilecorp.comN

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)

June 15, 2026 | newsfilecorp.comN

Lisata Therapeutics, Inc.: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

June 10, 2026 | finanznachrichten.de

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

June 10, 2026 | proactiveinvestors.com

Lisata Therapeutics Announces Tender Offer from Kuva Acquisition Corp at $4.00 per Share Plus Contingent Value Rights

June 10, 2026 | quiverquant.comQ

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

June 10, 2026 | globenewswire.com

Kuva and Lisata Therapeutics Tender Offer Update

June 1, 2026 | tennessean.comT

HC Wainwright & Co. downgrades Lisata Therapeutics (LSTA)

May 16, 2026 | msn.com

Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline

May 9, 2026 | theglobeandmail.com

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

May 4, 2026 | globenewswire.com

Lisata Therapeutics Delays Tender Offer Launch in Merger

April 3, 2026 | tipranks.com

Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications

March 26, 2026 | businesswire.com

Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances

March 10, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, BCLI, LSTA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.24 -0.01 (-5.46%)

As of 09/4/2026 04:00 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.05 -0.02 (-1.87%)

As of 09/4/2026 03:37 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Lisata Therapeutics NASDAQ:LSTA

$1.65 +0.01 (+0.61%)

As of 09/4/2026 03:59 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, BCLI, LSTA, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, BCLI, LSTA, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, BCLI, LSTA, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, BCLI, LSTA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Aptose Biosciences NASDAQ:APTO

Brainstorm Cell Therapeutics NASDAQ:BCLI

Lisata Therapeutics NASDAQ:LSTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APTO, BCLI, LSTA, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APTO, BCLI, LSTA, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APTO, BCLI, LSTA, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTO, BCLI, LSTA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Aptose Biosciences NASDAQ:APTO

Brainstorm Cell Therapeutics NASDAQ:BCLI

Lisata Therapeutics NASDAQ:LSTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools